FDA Approves Tobi Podhaler For Cystic Fibrosis
On March 22, 2013 the U.S. Food and Drug Administration announced approval of a new drug to treat a lung infection common in patients with cystic fibrosis. The drug, Tobi Podhaler (tobramycin inhalation powder) is approved for use in cystic fibrosis patients with Pseudomonas aeruginosa. P. aeruginosa is a bacterium that causes lung infections, which […]